Weight loss effect of glucagon‐like peptide‐1 mimetics on obese/overweight adults without diabetes: A systematic review and meta‐analysis of randomized controlled trials胰高血糖素样肽‐1类似物对非糖尿病肥胖/超重成人的减重作用：一篇对随机对照试验进行的系统评价及meta分析

Zhang, Fang; Tong, Yuzhen; Su, Na; Li, Yi; Tang, Lizhi; Huang, Li; Tong, Nanwei

doi:10.1111/1753-0407.12198

Cited by 59Pharmacology and Obesity TreatmentDiabetes Treatment and ManagementRegulation of Appetite and Obesity

Weight loss effect of glucagon‐like peptide‐1 mimetics on obese/overweight adults without diabetes: A systematic review and meta‐analysis of randomized controlled trials胰高血糖素样肽‐1类似物对非糖尿病肥胖/超重成人的减重作用：一篇对随机对照试验进行的系统评价及meta分析

Zhang, Fang, Tong, Yuzhen, Su, Na, Li, Yi, Tang, Lizhi, Huang, Li, Tong, Nanwei·2015·Journal of Diabetes

DOI 10.1111/1753-0407.12198

Open this paper in CoChat — free account

Abstract

Background: Glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) benefit weight maintenance for diabetic patients. We performed a systematic review to evaluate its weight loss effect on obese/overweight patients without diabetes in randomized controlled trials (RCTs). Methods: Literature updated to M ay 5, 2014 from C ochrane L ibrary, MEDLINE, EMBASE and reference lists from relevant articles were identified. RCTs with GLP‐1 mimetics treating obese/overweight adults without diabetes for at least 12 weeks were assessed. Studies lacking primary measurements were excluded. Three authors extracted data independently. Either fixed‐effect or random‐effect models were used to calculate weighted mean differences (WMDs), combined relative risks (RR) and 95% confidence interval (CI) in meta‐analyses. Intertrial heterogeneity across studies was examined by I 2 and Q statistics. Results: A total of 1345 individuals retrieved from eight studies were involved and all included trials were of mild‐to‐moderate bias risks. Participants in GLP‐1RA groups achieved a larger weight loss than those in control groups (−2.85 kg, 95%CI −3.55 to −2.14), and liraglutide may work in a dose‐dependent fashion. GLP‐1RAs also reduced body mass index (BMI) and waist circumferences (WC) and benefited systolic blood pressure and triglyceride regulation. But GLP‐1RAs were associated with increased nausea and vomiting events. Conclusions: GLP‐1 mimetics induce a weight loss in addition to BMI and WC reduction in obese/overweight adults without diabetes. Further long‐term randomized trials and basic studies are required to investigate the mechanisms.

Integrity signals

Registry

Crossref · 10.1111/1753-0407.12198

Cites

50 of 50 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Long-acting GLP-1 receptor agonists have demonstrated improvements in CVD risk factors including waist circumference, SBP, triglycerides, HDL cholesterol, and LDL in individuals with obesity.
“Long-acting glucagon-like peptide-1 (GLP-1) receptor agonists have demonstrated promising weight reduction in recent studies, 14,15 together with improvements in CVD risk factors including waist circumference, systolic blood pressure (SBP), triglycerides, high-density lipoprotein (HDL) cholesterol, and lowdensity lipoprotein (LDL) in individuals with obesity.16,17”
From Tirzepatide reduces the predicted risk of atherosclerotic cardiovascular disease and improves cardiometabolic risk factors in adults with obesity or overweight: SURMOUNT-1 post hoc analysis (2024) · cites this paper as [16]

Follow-up report on the diagnosis of diabetes mellitus
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus* (2003) · Diabetes Care · doi:10.2337/diacare.26.11.3160 · Cited by 3,784 · see citing works
Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)
Buse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60659-0 · Cited by 1,503 · see citing works
Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults.
(1998) · PubMed · Cited by 1,264 · see citing works
Effects of liraglutide in the treatment of obesity: A randomised, double-blind, placebo-controlled study
Astrup, A., Rössner, S., Van Gaal, L., Rissanen, A., Niskanen, L., Al Hakim, M., Madsen, J., Rasmussen, M. F., & Lean, M. E. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61375-1 · Cited by 1,163 · see citing works
The Glucagon-Like Peptides
Kieffer, T. J., & Habener, J. F. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.6.0385 · Cited by 1,056 · see citing works
Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials
Vilsboll, T., Christensen, M., Junker, A. E., Knop, F. K., & Gluud, L. L. (2012) · BMJ · doi:10.1136/bmj.d7771 · Cited by 970 · see citing works
Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance Randomized Study
on behalf of the NN8022-1923 Investigators, Wadden, T. A., Hollander, P., Klein, S., Niswender, K., Woo, V, Hale, P. M., & Aronne, L. (2013) · International Journal of Obesity · doi:10.1038/ijo.2013.120 · Cited by 842 · see citing works
Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide
on behalf of the NN8022-1807 Investigators, Astrup, A., Carraro, R., Finer, N., Harper, A., Kunesova, M., Lean, M. E. J., Niskanen, L., Rasmussen, M. F., Rissanen, A., et al. (2012) · International Journal of Obesity · doi:10.1038/ijo.2011.158 · Cited by 757 · see citing works
Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years
Klonoff, D. C., Buse, J. B., Nielsen, L. L., Guan, X., Bowlus, C. L., Holcombe, J. H., Wintle, M. E., & Maggs, D. G. (2008) · Current Medical Research and Opinion · doi:10.1185/030079908x253870 · Cited by 699 · see citing works
Dysfunctional Adiposity and the Risk of Prediabetes and Type 2 Diabetes in Obese Adults
Neeland, I. J., Turer, A. T., Ayers, C. R., Powell‐Wiley, T. M., Vega, G. L., Farzaneh‐Far, R., Grundy, S. M., Khera, A., McGuire, D. K., & de Lemos, J. A. (2012) · JAMA · doi:10.1001/2012.jama.11132 · Cited by 650 · see citing works
A Meta-Analysis of the Effect of Glucagon-Like Peptide-1 (7–36) Amide on Ad Libitum Energy Intake in Humans
Verdich, C., Flint, A., Gutzwiller, J., Näslund, E. B., Beglinger, C., Hellström, P. M., Long, S. J., Morgan, L., Holst, J. J., & Astrup, A. V. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.9.7877 · Cited by 600 · see citing works
Effect of regression from prediabetes to normal glucose regulation on long-term reduction in diabetes risk: results from the Diabetes Prevention Program Outcomes Study
Perreault, L., Pan, Q., Mather, K. J., Watson, K. E., Hamman, R. F., & Kahn, S. E. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60525-x · Cited by 532 · see citing works
Overweight and obesity in China
Wu, Y. (2006) · BMJ · doi:10.1136/bmj.333.7564.362 · Cited by 454 · see citing works
Rapid Tachyphylaxis of the Glucagon-Like Peptide 1–Induced Deceleration of Gastric Emptying in Humans
Nauck, M. A., Kemmeries, G., Holst, J. J., & Meier, J. J. (2011) · Diabetes · doi:10.2337/db10-0474 · Cited by 392 · see citing works
The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity
Flint, A., Raben, A., Ersbøll, A., Holst, J., & Astrup, A. (2001) · International Journal of Obesity · doi:10.1038/sj.ijo.0801627 · Cited by 384 · see citing works
A Meta-Analysis of the Effect of Glucagon-Like Peptide-1 (7-36) Amide on Ad Libitum Energy Intake in Humans
Verdich, C. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.86.9.4382 · Cited by 340 · see citing works
Pharmacologic and Surgical Management of Obesity in Primary Care: A Clinical Practice Guideline from the American College of Physicians
Snow, V. T., Barry, P. P., Fitterman, N., Qaseem, A., & Weiss, K. B. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-7-200504050-00011 · Cited by 325 · see citing works
Effects of glucagon-like peptide 1 on appetite and body weight: focus on the CNS
van Bloemendaal, L., ten Kulve, J. S., la Fleur, S. E., Ijzerman, R. G., & Diamant, M. (2014) · Journal of Endocrinology · doi:10.1530/joe-13-0414 · Cited by 312 · see citing works
Comparison of single and combined treatment with exenatide and metformin on menstrual cyclicity in overweight women with polycystic ovary syndrome
Elkind-Hirsch, K., Marrioneaux, O., Bhushan, M., Vernor, D., & Bhushan, R. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0115 · Cited by 276 · see citing works
Diagnosis and Management of Prediabetes in the Continuum of Hyperglycemia—When Do the Risks of Diabetes Begin? A Consensus Statement From the American College of Endocrinology and the American Association of Clinical Endocrinologists*
Garber, A. J., Handelsman, Y., EINHORN, D. F., Bergman, D. A., Bloomgarden, Z. T., Fonseca, V. A., Garvey, W. T., Gavin, J. R., Grunberger, G., Horton, E. S., et al. (2008) · Endocrine Practice · doi:10.4158/ep.14.7.933 · Cited by 235 · see citing works
Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre-diabetes
Rosenstock, J., Klaff, L. J., Schwartz, S., Northrup, J., Holcombe, J. H., Wilhelm, K., & Trautmann, M. (2010) · Diabetes Care · doi:10.2337/dc09-1203 · Cited by 229 · see citing works
Liraglutide: short‐lived effect on gastric emptying—long lasting effects on body weight
Jelsing, J., Vrang, N., Hansen, G., Raun, K., Tang‐Christensen, M., & Knudsen, L. B. (2012) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01557.x · Cited by 175 · see citing works
Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin
Jensterle Sever, M., Kocjan, T., Pfeifer, M., Kravos, N. A., & Janez, A. (2014) · European Journal of Endocrinology · doi:10.1530/eje-13-0797 · Cited by 175 · see citing works
Exenatide suppresses postprandial elevations in lipids and lipoproteins in individuals with impaired glucose tolerance and recent onset type 2 diabetes mellitus
Schwartz, E. A., Koska, J., Mullin, M. P., Syoufi, I., Schwenke, D. C., & Reaven, P. D. (2010) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2010.05.028 · Cited by 173 · see citing works
Short-Term Exenatide Treatment Leads to Significant Weight Loss in a Subset of Obese Women Without Diabetes
Dushay, J. R., Gao, C., Gopalakrishnan, G. S., Crawley, M. B., Mitten, E. K., Wilker, E. H., Mullington, J. M., & Maratos–Flier, E. (2011) · Diabetes Care · doi:10.2337/dc11-0931 · Cited by 149 · see citing works
Glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes: Differences and similarities
Lund, A., Knop, F. K., & Vilsbøll, T. (2014) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2014.03.005 · Cited by 148 · see citing works
Type 2 Diabetes Can Be Prevented With Early Pharmacological Intervention
DeFronzo, R. A., & Abdul‐Ghani, M. A. (2011) · Diabetes Care · doi:10.2337/dc11-s221 · Cited by 148 · see citing works
The role of glucagon‐like peptide‐1 impairment in obesity and potential therapeutic implications
Madsbad, S. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12119 · Cited by 146 · see citing works
Effect of GLP-1 Mimetics on Blood Pressure and Relationship to Weight Loss and Glycemia Lowering: Results of a Systematic Meta-Analysis and Meta-Regression
Katout, M., Zhu, H., Rutsky, J., Shah, P., Brook, R. D., Zhong, J., & Rajagopalan, S. (2013) · American Journal of Hypertension · doi:10.1093/ajh/hpt196 · Cited by 141 · see citing works
Intravenous infusion of glucagon-like peptide-1 potently inhibits food intake, sham feeding, and gastric emptying in rats
Chelikani, P. K., Haver, A. C., & Reidelberger, R. D. (2005) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00870.2004 · Cited by 128 · see citing works
Benefits of Liraglutide Treatment in Overweight and Obese Older Individuals With Prediabetes
Kim, S. H., Abbasi, F., Lamendola, C. A., Liu, A., Ariel, D., Schaaf, P., Grove, K., Tomasso, V., Ochoa, H., Liu, Y. V., et al. (2013) · Diabetes Care · doi:10.2337/dc13-0354 · Cited by 118 · see citing works
Comparative effects of the long-acting GLP-1 receptor ligands, liraglutide and exendin-4, on food intake and body weight suppression in rats
Hayes, M. R., Kanoski, S. E., Alhadeff, A. L., & Grill, H. J. (2011) · Obesity · doi:10.1038/oby.2011.50 · Cited by 110 · see citing works
Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme
Niswender, K. D., Pi‐Sunyer, X., Buse, J. B., Jensen, K. H., Toft, A. D., Russell-Jones, D. L., & Zinman, B. (2012) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01673.x · Cited by 100 · see citing works
Effects of Glucagon-Like Peptide-1 Receptor Agonists on Body Weight: A Meta-Analysis
Monami, M., Dicembrini, I., Marchionni, N., Rotella, C. M., & Mannucci, E. (2012) · Experimental Diabetes Research · doi:10.1155/2012/672658 · Cited by 99 · see citing works
Effects of Exenatide vs. Metformin on endothelial function in obese patients with pre-diabetes: a randomized trial
Kelly, A. S., Bergenstal, R. M., Gonzalez-Campoy, J., Katz, H., & Bank, A. J. (2012) · Cardiovascular Diabetology · doi:10.1186/1475-2840-11-64 · Cited by 98 · see citing works
Comparison of the hypoglycemic effect of acarbose monotherapy in patients with type 2 diabetes mellitus consuming an Eastern or Western diet: a systematic meta-analysis.
Zhu, Q.-B., Tong, Y.-Z., Wu, T.-X., Li, J.-Q., & Tong, N.-W. (2013) · Clinical Therapeutics · doi:10.1016/j.clinthera.2013.03.020 · Cited by 85 · see citing works
Self-citation
Energy expenditure by intravenous administration of glucagon-like peptide-1 mediated by the lower brainstem and sympathoadrenal system
Osaka, T., Endo, M., Yamakawa, M., & Inoue, S. (2005) · Peptides · doi:10.1016/j.peptides.2005.02.016 · Cited by 84 · see citing works
Impaired Secretion of Total Glucagon-like Peptide-1 in People with Impaired Fasting Glucose Combined Impaired Glucose Tolerance
Zhang, F., Tang, X., Cao, H., Lü, Q., Li, N., Liu, Y., Zhang, X., Zhang, Y., Cao, M., Wan, J., et al. (2012) · International Journal of Medical Sciences · doi:10.7150/ijms.4128 · Cited by 64 · see citing works
Self-citation
Is there a place for incretin therapies in obesity and prediabetes?
Holst, J. J., & Deacon, C. F. (2013) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2013.01.004 · Cited by 44 · see citing works
Prediabetes: To treat or not to treat?
Moutzouri, E., Tsimihodimos, V., Rizos, E. C., & Elisaf, M. (2011) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2011.10.007 · Cited by 30 · see citing works
Glucagon-like peptide-1 receptor agonists for weight loss in adult patients without diabetes
Ottney, A. R. (2013) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp130081 · Cited by 25 · see citing works
What are the risks and the benefits of current and emerging weight-loss medications?
Robinson, J. R., & Niswender, K. D. (2009) · Current Diabetes Reports · doi:10.1007/s11892-009-0058-x · Cited by 24 · see citing works
Pharmacological intervention in prediabetes: considering the risks and benefits
Prato, S. D., Bianchi, C., Miccoli, R., & Penno, G. (2007) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2007.00766.x · Cited by 22 · see citing works
What is the best treatment for prediabetes?
Sharma, M. D., & Garber, A. J. (2009) · Current Diabetes Reports · doi:10.1007/s11892-009-0053-2 · Cited by 21 · see citing works
Is the GLP-1 system a viable therapeutic target for weight reduction?
Tong, J., & Sandoval, D. A. (2011) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-011-9170-8 · Cited by 19 · see citing works
Exenatide as a Novel Weight Loss Modality in Patients Without Diabetes
Moreno, J., Willett, K. C., & Desilets, A. R. (2012) · Annals of Pharmacotherapy · doi:10.1345/aph.1r372 · Cited by 15 · see citing works
Liraglutide for weight loss in obese people – Authors' reply
Astrup, A. V., Rössner, S., Gaal, L. V., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60227-9 · Cited by 5 · see citing works
State of the Art Review: Long-term Pharmacotherapy for Overweight and Obesity: A Review of Sibutramine, Orlistat, and Rimonabant
Dunican, K. C., Desilets, A. R., & DeBellis, R. J. (2007) · American Journal of Lifestyle Medicine · doi:10.1177/1559827607303256 · Cited by 3 · see citing works
Off-label GLP-1 agonist treatment in 43 non-diabetic patients: are weight loss and treatment tolerance equally promising outside of clinical trials?
Sauer, N., Rohani, Z. S., Wiesch, C. S. Z., et al. (2013) · Endocrine Abstracts · doi:10.1530/endoabs.32.p760 · Cited by 1 · see citing works
Off-label GLP-1 agonist treatment in 43 non-diabetic patients: Are weight loss and treatment tolerance equally promising outside of clinical trials?
Sauer, N., Wiesch, C. S. Z., Reining, F., et al. (2013) · Diabetologie und Stoffwechsel · doi:10.1055/s-0033-1347764 · Cited by 1 · see citing works

Flagged first, then by citations

Sorted by citations

GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects
Zhao, X., Wang, M., Wen, Z., Lu, Z., Cui, L., Fu, C., Xue, H., Liu, Y., & Zhang, Y. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.721135 · Cited by 463 · see citing works
<scp>GLP</scp> ‐1 receptor agonists: Nonglycemic clinical effects in weight loss and beyond
Ryan, D., & Acosta, A. (2015) · Obesity · doi:10.1002/oby.21107 · Cited by 112 · see citing works
Tirzepatide reduces the predicted risk of atherosclerotic cardiovascular disease and improves cardiometabolic risk factors in adults with obesity or overweight: SURMOUNT-1 post hoc analysis
Hankosky, E. R., Wang, H., Neff, L. M., Kan, H., Wang, F., Ahmad, N. N., Griffin, R., Stefanski, A., & Garvey, W. T. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15318 · Cited by 97 · see citing works
Efficacy and safety of semaglutide on weight loss in obese or overweight patients without diabetes: A systematic review and meta-analysis of randomized controlled trials
Gao, X., Hua, X., Wang, X., Xu, W., Zhang, Y., Shi, C., & Gu, M. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.935823 · Cited by 81 · see citing works
Dapagliflozin once daily plus exenatide once weekly in obese adults without diabetes: <scp>S</scp> ustained reductions in body weight, glycaemia and blood pressure over 1 year
Lundkvist, P., Pereira, M. J., Katsogiannos, P., Sjöström, C. D., Johnsson, E., & Eriksson, J. W. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12954 · Cited by 72 · see citing works
Efficacy and safety of glucagon-like peptide-1 receptor agonists in non-alcoholic fatty liver disease: A systematic review and meta-analysis
Dong, Y., Lv, Q., Li, S., Wu, Y., Li, L., Li, J., Zhang, F., Sun, X., & Tong, N. (2017) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2016.11.009 · Cited by 71 · see citing works
Self-citation
The Antiobesity Effect and Safety of GLP-1 Receptor Agonist in Overweight/Obese Patients Without Diabetes: A Systematic Review and Meta-Analysis
Guo, X., Zhou, Z., Lyu, X., Xu, H., Zhu, H., Pan, H., Wang, L., Yang, H., & Gong, F. (2022) · Hormone and Metabolic Research · doi:10.1055/a-1844-1176 · Cited by 59 · see citing works
Glucagon-like peptide-1 agonists combating clozapine-associated obesity and diabetes
Mayfield, K., Siskind, D., Winckel, K., Russell, A. W., Kisely, S., Smith, G., & Hollingworth, S. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881115625496 · Cited by 49 · see citing works
Tirzepatide reduces the predicted risk of developing type 2 diabetes in people with obesity or overweight: Post hoc analysis of the <scp>SURMOUNT</scp> ‐1 trial
Hankosky, E. R., Wang, H., Neff, L. M., Kan, H., Wang, F., Ahmad, N. N., Stefanski, A., & Garvey, W. T. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15269 · Cited by 44 · see citing works
Nonsurgical weight loss interventions: a systematic review of systematic reviews and meta-analyses
Twells, L. K., Harris Walsh, K., Blackmore, A., Adey, T., Donnan, J., Peddle, J., Ryan, D., Farrell, A., Nguyen, H., Gao, Z., et al. (2021) · Obesity Reviews · doi:10.1111/obr.13320 · Cited by 33 · see citing works
Circulating adiponectin levels in type 2 diabetes mellitus patients with or without non-alcoholic fatty liver disease: Results of a small, open-label, randomized controlled intervention trial in a subgroup receiving short-term exenatide
Savvidou, S., Karatzidou, K., Tsakiri, K., Gagalis, A., Hytiroglou, P., & Goulis, J. (2016) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2015.12.003 · Cited by 30 · see citing works

Authors: Zhang, F., Tong, Y., Su, N., Li, Y., Tang, L., Huang, L., & Tong, N.
Affiliations: West China Medical Center of Sichuan University (CN)
Sichuan University (CN)
West China Hospital of Sichuan University (CN)
Joslin Diabetes Center (US)
Corresponding author: Tong, Nanwei
ORCID: Zhang, Fang
Su, Na
Li, Yi
Huang, Li
Tong, Nanwei
Venue: Journal of Diabetes
Publisher: Wiley
Published: 2014-09-10
Volume: 7
Issue: 3
Pages: 329-339
ISSN: 1753-0393 (ISSN-L)
1753-0407
DOI: 10.1111/1753-0407.12198
OpenAlex: W2145662952
Cited by: 59
References: 50
Citations by year: 2026: 2 · 2025: 8 · 2024: 3 · 2023: 4 · 2022: 10 · 2021: 5 · 2020: 3 · 2019: 3 · 2018: 5 · 2017: 4 · 2016: 6 · 2015: 6
FWCI: 0.68
Type: journal article
Language: en
Open access: closed
Licence: onlinelibrary.wiley.com/termsAndConditions#vor (vor)
Locations: Journal of Diabetes (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Pharmacology › Pharmacology and Obesity Treatment
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
Keywords: GLP-1 receptor agonists, weight loss, obesity, overweight, non-diabetic adults, liraglutide, dose-dependent effects, body mass index, waist circumference, systolic blood pressure, triglycerides, nausea and vomiting
MeSH terms: Adult, Humans, Hypoglycemic Agents, Obesity, Weight Loss, Randomized Controlled Trials as Topic, Receptors, Glucagon, Biomimetics, Overweight, Glucagon-Like Peptide 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Cites

Cited by

Related

Record

About these checks